Cargando…

High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma

INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with poor response to immune checkpoint inhibitors. The mechanism of such poor response is not completely understood. METHODS: We assessed T-cell receptor (TCR) repertoire and RNA expression at the single-ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Yu, Gao, Jianfeng, Lin, Jiajing, Ma, Yuan, Hou, Zelin, Lin, Yali, Wen, Shi, Pan, Minggui, Lu, Fengchun, Huang, Heguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281055/ https://www.ncbi.nlm.nih.gov/pubmed/37347110 http://dx.doi.org/10.3389/fendo.2023.1181538

Ejemplares similares

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer
por: Hou, Zelin, et al.
Publicado: (2023)

Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer
por: Pan, Yu, et al.
Publicado: (2019)

Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
por: Pan, Yu, et al.
Publicado: (2019)

High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer
por: Fei, Qinglin, et al.
Publicado: (2020)

WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC
por: Pan, Yu, et al.
Publicado: (2018)

Ulinastatin ameliorates tissue damage of severe acute pancreatitis through modulating regulatory T cells
por: Pan, Yu, et al.
Publicado: (2017)

Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer
por: Hou, Zelin, et al.
Publicado: (2020)

Metabonomic changes from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma in tissues from rats
por: Wen, Shi, et al.
Publicado: (2016)

Interplay Between Diabetes and Pancreatic Ductal Adenocarcinoma and Insulinoma: The Role of Aging, Genetic Factors, and Obesity
por: Duvillié, Bertrand, et al.
Publicado: (2020)

Serum metabolomic profiling unveils distinct sex-related metabolic patterns in NAFLD
por: Fotakis, Charalambos, et al.
Publicado: (2023)

Observational study of surgical resection in small non-functional pancreatic neuroendocrine tumors: AS SEER-based study
por: Lin, Jiajing, et al.
Publicado: (2023)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

Proteome alterations in pancreatic ductal adenocarcinoma
por: Pan, Sheng, et al.
Publicado: (2020)

Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma
por: Ni, Bo, et al.
Publicado: (2023)

Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma
por: Yu, Xiang, et al.
Publicado: (2017)

Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma
por: Schnipper, Julie, et al.
Publicado: (2020)

Pancreatic Ductal Adenocarcinoma Induces Neural Injury that Promotes a Transcriptomic and Functional Repair Signature by Peripheral Neuroglia
por: Weitz, Jonathan, et al.
Publicado: (2023)

A high serum creatine kinase (CK)-MB-to-total-CK ratio in patients with pancreatic cancer: a novel application of a traditional marker in predicting malignancy of pancreatic masses?
por: Chen, Cong, et al.
Publicado: (2023)

Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA
por: Wu, Huanwen, et al.
Publicado: (2022)

Oral mycobiota and pancreatic ductal adenocarcinoma
por: Wei, Ailin, et al.
Publicado: (2022)

Integrating multiple machine learning methods to construct glutamine metabolism-related signatures in lung adenocarcinoma
por: Zhang, Pengpeng, et al.
Publicado: (2023)

Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal Adenocarcinoma
por: Chen, Yusheng, et al.
Publicado: (2023)

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)

Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
por: Chen, Dung-Tsa, et al.
Publicado: (2015)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma
por: Zhang, Deyu, et al.
Publicado: (2022)

Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
por: Ren, Min, et al.
Publicado: (2023)

Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma
por: Mascharak, Shamik, et al.
Publicado: (2023)

Development and validation of a simple-to-use nomogram to predict liver metastasis in patients with pancreatic neuroendocrine neoplasms: a large cohort study
por: Pan, Maoen, et al.
Publicado: (2021)

Correction: Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
Publicado: (2018)

Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice
por: Yue, Lin, et al.
Publicado: (2022)

A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma
por: Haider, Syed, et al.
Publicado: (2014)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
por: Wang, Weijia, et al.
Publicado: (2021)

Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma
por: Chen, Dongjie, et al.
Publicado: (2021)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma
por: Li, Tiandong, et al.
Publicado: (2023)

A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection
por: He, Chaobin, et al.
Publicado: (2019)

A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma
por: Li, Ang, et al.
Publicado: (2022)

A functional genetic screen for metabolic proteins unveils GART and the de novo purine biosynthetic pathway as novel targets for the treatment of luminal A ERα expressing primary and metastatic invasive ductal carcinoma
por: Cipolletti, Manuela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o74egkniakeonh6q3bnglb5pv0